Avadel Pharmaceuticals PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Janus Henderson Group plc reported a 1.9% beneficial ownership stake in Avadel Pharmaceuticals PLC, holding 1,823,865 ordinary shares as of December 31, 2025.
Brandes Investment Partners, L.P. reported a 0.22% passive stake in Avadel Pharmaceuticals PLC, holding 218,835 common shares.
Tontine Asset Associates, Tontine Capital Overseas Master Fund II, and Jeffrey L. Gendell have filed an exit Schedule 13G/A, reporting their beneficial ownership in Avadel Pharmaceuticals plc has fallen below 5%.
Janus Henderson Group plc has reported an increased beneficial ownership of 7.7% in Avadel Pharmaceuticals PLC's common stock, holding 7,429,718 shares.
Janus Henderson Group plc has increased its beneficial ownership in Avadel Pharmaceuticals PLC to 11.5% of common stock, holding 11,132,131 shares as of June 30, 2025.
Two Seas Capital LP, along with its general partner and chief investment officer, reported a 6.4% beneficial ownership stake in Avadel Pharmaceuticals plc.
The Vanguard Group has reported a passive beneficial ownership of 5.74% of Avadel Pharmaceuticals PLC's common stock as of June 30, 2025.
The Vanguard Group has reported a 5.74% beneficial ownership stake in Avadel Pharmaceuticals PLC, held for passive investment purposes.
SCHEDULE 13G/A: BlackRock Discloses 7.0% Passive Stake in Avadel Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.0% beneficial ownership stake in Avadel Pharmaceuticals' common stock as of June 30, 2025.
Two Seas Capital LP, along with its general partner Two Seas Capital GP LLC and chief investment officer Sina Toussi, has reported a passive 5.1% beneficial ownership stake in Avadel Pharmaceuticals plc.
Brandes Investment Partners, L.P. has reported a 5.87% beneficial ownership stake in Avadel Pharmaceuticals PLC, holding 5,670,682 common shares as of March 31, 2025.
SCHEDULE 13G/A: Janus Henderson Group Maintains Significant Stake in Avadel Pharmaceuticals, Amending Beneficial Ownership to 14.1%
Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have filed an amendment to their Schedule 13G, disclosing continued beneficial ownership of 14.1% of Avadel Pharmaceuticals PLC's common stock as of March 31, 2025.
Janus Henderson Group PLC and its affiliates have disclosed a passive beneficial ownership of 14.6% in Avadel Pharmaceuticals PLC, primarily through its various investment entities.